Literature DB >> 31377983

Upregulated Expression of CUX1 Correlates with Poor Prognosis in Glioma Patients: a Bioinformatic Analysis.

Xiujie Wu1, Fan Feng2, Chuanchao Yang3, Moxuan Zhang3, Yanhao Cheng1, Yayun Zhao4, Yayu Wang5, Fengyuan Che1, Jian Zhang6, Xueyuan Heng7.   

Abstract

Cut-like homeobox-1 (CUX1) is expressed in the upper layer of the cortex and participates in DNA replication, cell cycle control, and DNA repair. It has been shown to be involved in the proliferation of various types of solid tumors. The aims of this study were to explore the relationship between CUX1 expression and the prognosis of glioma by performing a series of functional experiments and bioinformatic analyses. Firstly, we found that CUX1 expression levels differed among patients with different grades of gliomas, and they were significantly correlated with the prognosis of glioma patients according to an analysis of data from a public database. qRT-PCR, western blotting, and immunohistochemical analysis of CUX1 were performed to demonstrate that the expression of CUX1 was positively correlated with the glioma WHO grade (P < 0.05) and several malignant clinical pathological parameters, including Ki67 and P53mut. In addition, the multivariate Cox regression and Kaplan-Meier curves showed that CUX1 expression exerted predictive value for overall survival. Finally, to further investigate the functions of CUX1, we identified CUX1-associated genes and, though GO/KEGG analysis, their associated biological functions and signaling pathways; the results suggested that the activity of CUX1 might be exerted via the JAK-STAT pathway or other key regulators of the cell cycle to promote proliferation, inflammation, and chemotherapy resistance in glioma. Taken together, these results indicate that CUX1 is a potential biomarker of malignancy and prognosis and may serve as a potential therapeutic target for glioma patients.

Entities:  

Keywords:  Bioinformatic analysis; CUX1; Glioma; Malignancy; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31377983     DOI: 10.1007/s12031-019-01355-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  41 in total

1.  The transcription factor CUTL1 is associated with proliferation and prognosis in malignant melanoma.

Authors:  Xing Fan; Honghong Wang; Jinfeng Zhou; Shiping Wang; Xiangwei Zhang; Tong Li; Yongzhan Nie; Bin Liu
Journal:  Melanoma Res       Date:  2014-06       Impact factor: 3.599

2.  IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.

Authors:  Caroline Hilmi; Lionel Larribere; Sandy Giuliano; Karine Bille; Jean-Paul Ortonne; Robert Ballotti; Corine Bertolotto
Journal:  J Invest Dermatol       Date:  2007-12-13       Impact factor: 8.551

3.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordan Xu; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2016-10-01       Impact factor: 12.300

Review 4.  Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.

Authors:  Erwin G Van Meir; Costas G Hadjipanayis; Andrew D Norden; Hui-Kuo Shu; Patrick Y Wen; Jeffrey J Olson
Journal:  CA Cancer J Clin       Date:  2010 May-Jun       Impact factor: 508.702

5.  CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer.

Authors:  S Ripka; A Neesse; J Riedel; E Bug; A Aigner; R Poulsom; S Fulda; J Neoptolemos; W Greenhalf; P Barth; T M Gress; P Michl
Journal:  Gut       Date:  2010-05-04       Impact factor: 23.059

6.  CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness.

Authors:  Patrick Michl; Antoine R Ramjaun; Olivier E Pardo; Patricia H Warne; Martin Wagner; Richard Poulsom; Corrado D'Arrigo; Kenneth Ryder; Andre Menke; Thomas Gress; Julian Downward
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

7.  p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin.

Authors:  Valerie Kedinger; Laurent Sansregret; Ryoko Harada; Charles Vadnais; Chantal Cadieux; Kelly Fathers; Morag Park; Alain Nepveu
Journal:  J Biol Chem       Date:  2009-07-27       Impact factor: 5.157

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Authors:  Zubaidah M Ramdzan; Charles Vadnais; Ranjana Pal; Guillaume Vandal; Chantal Cadieux; Lam Leduy; Sayeh Davoudi; Laura Hulea; Lu Yao; Anthony N Karnezis; Marilène Paquet; David Dankort; Alain Nepveu
Journal:  PLoS Biol       Date:  2014-03-11       Impact factor: 8.029

10.  Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.

Authors:  Charles Vadnais; Peiman Shooshtarizadeh; Charles V Rajadurai; Robert Lesurf; Laura Hulea; Sayeh Davoudi; Chantal Cadieux; Michael Hallett; Morag Park; Alain Nepveu
Journal:  Biol Open       Date:  2014-09-12       Impact factor: 2.422

View more
  3 in total

1.  Overexpressed P75CUX1 promotes EMT in glioma infiltration by activating β-catenin.

Authors:  Anqi Xu; Xizhao Wang; Jie Luo; Mingfeng Zhou; Renhui Yi; Tengyue Huang; Jie Lin; Zhiyong Wu; Cheng Xie; Shengfeng Ding; Yu Zeng; Ye Song
Journal:  Cell Death Dis       Date:  2021-02-04       Impact factor: 8.469

2.  CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation.

Authors:  Heidi Griesmann; Sebastian Mühl; Jan Riedel; Katharina Theuerkorn; Bence Sipos; Irene Esposito; Gregory B Vanden Heuvel; Patrick Michl
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

Review 3.  CUX1, A Controversial Player in Tumor Development.

Authors:  Ning Liu; Qiliang Sun; Long Wan; Xuan Wang; Yu Feng; Judong Luo; Hailong Wu
Journal:  Front Oncol       Date:  2020-05-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.